Navigation Links
Samaritan Partners 'Forgetful' Rat Model to Taconic to Commercialize
Date:10/1/2008

The Samaritan Alzheimer's Rat Model

- Mimics Human Alzheimer's

- Speeds 'Race for Time' to Find Cure

- Saves Valuable Research Money

LAS VEGAS, Oct. 1 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals (OTC Bulletin Board: SPHC) (http://www.samaritanpharma.com) and Taconic Farms, Hudson, New York, are pleased to announce they have inked a worldwide partnering agreement to commercialize "The Samaritan Alzheimer's Rat Model." The "forgetful" rat model is a research tool used by scientists to study the effectiveness of their new drugs to treat Alzheimer's disease. The unique benefits of the rat model lie in its ability,

-- To mimic many features of human Alzheimer's including memory loss,

-- Speed a scientist's "race for time" in finding a cure for the

mind-robbing disease

-- Save scientists valuable research money.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081001/LAW054)

The rat model is now available exclusively through Taconic. Samaritan will receive royalties on net sales. Financial terms were not disclosed.

"Taconic is extremely pleased to offer researchers a new and potentially invaluable weapon in the war on neurodegenerative disease," said Todd Little, President of Taconic. "The rapid time to disease state of the Samaritan Alzheimer's Rat Model will enable investigators to conduct Alzheimer's drug target screening on a much faster timeline than ever before."

The rat model is published in Pharmacology, 2006;76:19-33

"Taconic provides us with an experienced partner to monetize this unique animal model to 'rat out' Alzheimer's. The rat model is groundbreaking, in that it offers significant advantages over other options previously available for the study of Alzheimer's. We anticipate Taconic achieving and surpassing projected market penetrations in international markets," said Dr. Greeson, CEO, Samaritan Pharmaceuticals.

Samaritan's Phase I, Alzheimer's drug Caprospinol (SP-233), utilized "The Samaritan Alzheimer's Rat Model." and the Morris Water Maze, in an IND enabling, proof of concept study. Treated rats demonstrated Caprospinol's efficacy by,
-- clearing beta-amyloid plaque formation

-- restoring the memory of tested rats

-- protecting mitochondria function

-- protecting cell viability

-- decreasing cell death

Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures."

Samaritan Pharmaceuticals is a biopharmaceutical company committed to bringing innovative life-saving drugs to suffering patients. Samaritan website: http://www.samaritanpharma.com. Please register for upcoming conference calls, news, and events.

Taconic Farms, Inc.

Taconic was founded in 1952 as a family-owned business in New York's Hudson River Valley. Since then, the company has become one of the largest laboratory rodent providers in the world with a reputation for consistently producing high quality, well-defined rats and mice. Taconic has six breeding facilities and three service laboratories in the USA and Europe, a staff of over 900, and a commitment to technological innovation. Taconic website, http://www.taconic.com

Disclaimer

The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 14, 2008. The company undertakes no duty to update forward-looking statements.

Samaritan Pharma Contact: Barrie Fuller 702-735-7001 barriefuller@samaritanpharma.com


'/>"/>
SOURCE Samaritan Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
2. Riverside Partners Sells MicroCal to GE Healthcare
3. onTargetjobs and ClearedConnections Announce Online Recruitment Partnership
4. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
5. Satyam Partners with Oracle to Provide Clinical Development Applications
6. alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
7. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
8. Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
11. NIST and partners identify tiny gold clusters as top-notch catalysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Cumberland Foreside, Maine (PRWEB) , ... January 17, ... ... to announce the addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration ... and Rheumatoid Factor in a human serum base. Each VALIDATE® SP2 kit is ...
(Date:1/17/2017)... DIEGO , Jan. 17, 2017  An ... School of Medicine and St. Boniface Hospital Albrechtsen ... for peripheral neuropathy, an unmet health need affecting ... the Journal of Clinical Investigation, their results identify ... that prevent and reverse neuronal injury in animal ...
(Date:1/17/2017)... 2017   Pulmatrix, Inc . (NASDAQ: ... inhaled therapies to address serious pulmonary diseases, today announced ... the lungs of CF patients, PUR1900, has been designated ... U.S. Food & Drug Administration. Under ... the development of novel drugs against important pathogens, Pulmatrix ...
(Date:1/17/2017)...  Only nine percent of U.S. consumers believe pharmaceutical ... 16 percent believe health insurance companies do, according to ... of U.S. adults believe health care providers (such as ... hospitals (23%). "We are in the midst ... , vice president of reputation management and public affairs ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
(Date:12/7/2016)... , December 7, 2016 According to a new market ... Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region ... to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by ... Continue Reading ... MarketsandMarkets ...
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
Breaking Biology News(10 mins):